Loading company…
Pneumagen Ltd is a UK biotechnology company developing Neumifil, an intranasal treatment for viral respiratory infections.
Pneumagen Ltd is a UK biotechnology company founded in 2016 that develops treatments for respiratory viral infections. Its lead product, Neumifil, is an intranasal drug designed to prevent and treat infections such as influenza, RSV, human rhinovirus and SARS-CoV-2. A Phase 2 Human Challenge Study showed statistically significant results in lowering symptomatic influenza infections. The company raised GBP 8 million on June 1, 2023 from Esperante Ventures, Scottish Investment Bank and Thairm Bio, and Douglas Thomson is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in